Editor’s summary Dravet syndrome (DS) is a severe and difficult-to-treat epileptic syndrome usually caused by a loss-of-function mutation in SCN1A, which encodes the voltage-gated sodium channel 1.1 (NaV1.1), resulting in interneuron inhibitory dysfunction. Here, Mich and colleagues developed a gene replacement therapy for DS that specifically targets these interneurons.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Jiyun
Contact Jiyun, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack